HBSP (USA)
-
BeiGene
Shih, Willy; Zhang, JimmyCase HBS-618033-EStrategyBeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeStarting at €8.20
-
BeiGene, PowerPoint Supplement
Shih, Willy; Zhang, JimmyCase HBS-618043-EStrategyPowerPoint slides for case 618033.Starting at €8.20
-
-
Crescent Petroleum-Dana Gas: Negotiate, Mediate, Arbitrate
Fabbe, Kristin E.; Reinert, Sophus A.; Cisneros, NathanCase HBS-718052-EEconomicsStarting at €8.20
-
Veracity Worldwide in Syria: Assessing Political Risk in a Volatile Environment
Musacchio, Aldo; Reinert, Sophus A.Case HBS-712009-EEconomicsThis case explores the dynamic set of political risks raised by a local-partner contract renewal within the context of Syria's unfolding political upheaval. Cambell Technologies, a US-based software firm, was evaluating whether to renew its licensing agreement with Elevate, its Damascus-based distributor. Elevate's strong sales performance and sound management seemed to justify a renewal of its agreement, but the possibility of political change i...Starting at €8.20
-
Bhutan: Governing for Happiness
Reinert, Sophus A.; Humphrey, Thomas; Safran, BenjaminCase HBS-715024-EEconomicsUnique among the world's countries, the Himalayan Kingdom of Bhutan had abandoned the traditional policy goal of increasing Gross Domestic Product (GDP) in favor of pursuing Gross National Happiness (GNH). Famously, Bhutan ranked highly on lists of the happiest countries in spite of a tumultuous history, a low life expectancy, a dismal literacy rate, a small and undiversified economy, and low GDP per capita. Everyone, it seemed, from tourists and...Starting at €8.20
-
BeiGene, Teaching Note
Shih, Willy; Zhang, JimmyTeaching Note HBS-618039-EStrategyTeaching Note for 618033 BeiGene. BeiGene was a biopharmaceutical company founded on exploiting a temporal regulatory policy discontinuity. Because of regulatory challenges in China, most innovative new drugs launched there four to six years after their initial U.S. launches. This gave BeiGene a window of opportunity to develop drug candidates toward known targets with known mechanisms of actions that would allow it to become first-in-class in Ch...Starting at €0.00
-
Indonesia-Unity in Diversity, Teaching Note
Reinert, Sophus A.Teaching Note HBS-718042-EEconomicsTeaching note for case 715035.Starting at €0.00
-
The Road to Mandalay: RMA Group in Myanmar
Reinert, Sophus A.; Fulwiler, MariaCase HBS-719003-EEconomicsStarting at €8.20